UM1TR006031
Cooperative Agreement
Overview
Grant Description
Advancing personalized cardiac organoids - converging in vitro, in chemico, and in silico models - project summary/abstract
Cardiac disease remains the leading cause of mortality, yet existing models fail to capture the complexity necessary for effective therapeutic development.
COIN (Cardiac Organoids in Niches) integrates in silico, in chemico, and in vitro methodologies to engineer patient-specific cardiac niches, enhancing disease fidelity and therapeutic screening.
By leveraging AI-driven modeling, biomaterials engineering, and multi-omics analysis, COIN establishes a scalable, reproducible NAMS platform for disease modeling and drug discovery.
COIN’s AI-powered niche design tailors cardiac microenvironments to genetic, sex, and age profiles, improving disease relevance and therapeutic predictability.
Innovations in biomaterials engineering refine extracellular matrix (ECM) properties to replicate human cardiac physiology, while organoid villages enhance translational accuracy.
Multi-scale validation ensures COIN models faithfully reproduce patient-specific disease phenotypes, supporting regulatory qualification and preclinical safety assessment.
COIN collaborates with the VQN to establish regulatory validation benchmarks and with the NDHCC to facilitate fair-compliant multi-omics data-sharing.
Supported by the nation’s largest academic iPSC biobank and the Stanford Center for Genomics and Personalized Medicine, COIN unites leading experts in bioinformatics, AI, biomaterials, and organoid engineering to develop standardized, regulatory-ready NAMS models.
Comprehensive technical characterization ensures functional validation, disease fidelity, and industry readiness.
Training and outreach initiatives drive interdisciplinary collaboration and workforce development, fostering broad industry adoption.
By integrating multi-scale modeling, high-throughput biomaterials engineering, and AI-driven analytics, COIN reduces reliance on animal models, advances precision drug discovery, and establishes a gold-standard NAMS platform for cardiac medicine.
Cardiac disease remains the leading cause of mortality, yet existing models fail to capture the complexity necessary for effective therapeutic development.
COIN (Cardiac Organoids in Niches) integrates in silico, in chemico, and in vitro methodologies to engineer patient-specific cardiac niches, enhancing disease fidelity and therapeutic screening.
By leveraging AI-driven modeling, biomaterials engineering, and multi-omics analysis, COIN establishes a scalable, reproducible NAMS platform for disease modeling and drug discovery.
COIN’s AI-powered niche design tailors cardiac microenvironments to genetic, sex, and age profiles, improving disease relevance and therapeutic predictability.
Innovations in biomaterials engineering refine extracellular matrix (ECM) properties to replicate human cardiac physiology, while organoid villages enhance translational accuracy.
Multi-scale validation ensures COIN models faithfully reproduce patient-specific disease phenotypes, supporting regulatory qualification and preclinical safety assessment.
COIN collaborates with the VQN to establish regulatory validation benchmarks and with the NDHCC to facilitate fair-compliant multi-omics data-sharing.
Supported by the nation’s largest academic iPSC biobank and the Stanford Center for Genomics and Personalized Medicine, COIN unites leading experts in bioinformatics, AI, biomaterials, and organoid engineering to develop standardized, regulatory-ready NAMS models.
Comprehensive technical characterization ensures functional validation, disease fidelity, and industry readiness.
Training and outreach initiatives drive interdisciplinary collaboration and workforce development, fostering broad industry adoption.
By integrating multi-scale modeling, high-throughput biomaterials engineering, and AI-driven analytics, COIN reduces reliance on animal models, advances precision drug discovery, and establishes a gold-standard NAMS platform for cardiac medicine.
Funding Goals
<P><SPAN STYLE="BACKGROUND-COLOR:WHITE;">THE OFFICE OF STRATEGIC COORDINATION (</SPAN><A HREF="HTTPS://COMMONFUND.NIH.GOV/"><SPAN STYLE="BACKGROUND-COLOR:WHITE;">COMMON FUND</SPAN></A><SPAN STYLE="BACKGROUND-COLOR:WHITE;">)</SPAN><SPAN STYLE="BACKGROUND-COLOR:#F9F9F9;"> SUPPORTS RESEARCH AND OTHER PROJECTS THAT WILL ACCELERATE FUNDAMENTAL BIOMEDICAL DISCOVERY AND TRANSLATION OF THAT KNOWLEDGE INTO EFFECTIVE PREVENTION STRATEGIES AND NEW TREATMENTS.</SPAN></P>
Grant Program (CFDA)
Place of Performance
Stanford,
California
94305
United States
Geographic Scope
Single Zip Code
The Leland Stanford Junior University was awarded
Precision Cardiac Organoid Modeling for Therapeutic Development
Cooperative Agreement UM1TR006031
worth $3,091,157
from the National Institute of Allergy and Infectious Diseases in March 2026 with work to be completed primarily in Stanford California United States.
The grant
has a duration of 4 years 9 months and
was awarded through assistance program 93.310 Trans-NIH Research Support.
The Cooperative Agreement was awarded through grant opportunity Complement-ARIE New Approach Methodologies (NAMs) Technology Development Centers (UM1 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 4/6/26
Period of Performance
3/25/26
Start Date
12/31/30
End Date
Funding Split
$3.1M
Federal Obligation
$0.0
Non-Federal Obligation
$3.1M
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
UM1TR006031
SAI Number
UM1TR006031-2127153815
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NR00 NIH National Center for Advancing Translational Sciences
Funding Office
75NA00 NIH OFFICE OF THE DIRECTOR
Awardee UEI
HJD6G4D6TJY5
Awardee CAGE
1KN27
Performance District
CA-16
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Modified: 4/6/26